Eloxx Pharmaceuticals Inc（ELOX）股票分析

AI 分析 of Eloxx Pharmaceuticals Inc (ELOX)

持有

Eloxx Pharmaceuticals is currently not a strong buy due to its recent financial performance and technical indicators. The stock price is at $12.84, which is significantly below its 52-week high of $23.40, indicating a potential for recovery but also a risk of further decline. The RSI is at 39.31, suggesting that the stock is nearing oversold territory, but the recent 5-day change is down 2.51%, reflecting ongoing bearish sentiment. The company reported a net loss of $4.5 million in Q2 2026, which is a 137.5% increase in losses compared to the previous year, raising concerns about its profitability. However, the completion of a $66 million public offering and FDA clearance for a Phase 2 clinical trial could provide positive catalysts for future growth. The main risk is the ongoing losses, which have increased significantly, and the current ratio of 3.74 indicates a strong liquidity position but does not guarantee profitability in the near term.

分析師評級（1）

買進

1 買進

0 持有

0 賣出

目前: 12.44

最低

—

平均

—

最高

—

Guggenheim

買進

$40

2026-10-28

Guggenheim

2026-10-28

目標價

$40

買進

Leerink

優於大盤

$32

2026-09-18

Leerink

2026-09-18

目標價

$32

優於大盤

Lucid Capital

買進

$38

2026-08-20

Lucid Capital

2026-08-20

目標價

$38

買進

LifeSci Capital

優於大盤

$40

2026-07-22

LifeSci Capital

2026-07-22

目標價

$40

優於大盤

Guggenheim

買進

$43

2026-07-19

Guggenheim

2026-07-19

目標價

$43

買進

查看全部評級

估值指標

Eloxx Pharmaceuticals Inc（ELOX）目前預期本益比為 0.00，5 年平均預期本益比為 15.77。

預期本益比

嚴重低估

5 年均值 P/E

15.77

目前P/E

0.00

高估

15.77

低估

15.77

預期 EV/EBITDA

5 年均值 EV/EBITDA

目前EV/EBITDA

0.00

預期股價營收比

5 年均值 P/S

目前P/S

0.00

持有 ELOX 的大戶

E

EcoR1 Capital, LLC

+ 持有ELOX

+16.56%

3個月報酬率

ELOX 常見問題 —— 由 Alphio AI 解答

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders. It operates in the Healthcare sector.

Eloxx Pharmaceuticals is currently not a strong buy due to its recent financial performance and technical indicators. The stock price is at $12.84, which is significantly below its 52-week high of $23.40, indicating a potential for recovery but also a risk of further decline. The RSI is at 39.31, suggesting that the stock is nearing oversold territory, but the recent 5-day change is down 2.51%, reflecting ongoing bearish sentiment. The company reported a net loss of $4.5 million in Q2 2026, which is a 137.5% increase in losses compared to the previous year, raising concerns about its profitability. However, the completion of a $66 million public offering and FDA clearance for a Phase 2 clinical trial could provide positive catalysts for future growth. The main risk is the ongoing losses, which have increased significantly, and the current ratio of 3.74 indicates a strong liquidity position but does not guarantee profitability in the near term.

1 analysts cover ELOX: 1 rate it Buy, 0 Hold and 0 Sell.